Table 2 Genomic characteristics of patients with oncogene-driven mutations on TKI treatment
Patient ID | Age | Gender | Ethnicity | Driver Oncogene Mutation | PD-L1 IHC | TMB | TKI Treatment | Clinical response | RECIST V1.1 | PFS (mos) | OS (mos) |
|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 78 | F | Asian | EGFR exon 19 deletion | 0 | NA | Erlotinib, Osimertinib | Good | PR | 16.2 | 32.8 |
2 | 72 | F | Asian | EGFR L858R, EGFR T790M | 2% | 4 | Erlotinib, Afatinib, Osimertinib | Poor | PD | 7.7 | 46.6 |
3 | 76 | F | Asian | EGFR L858R | NA | NA | Gefitinib, Afatinib | Good | PR | 7 | 25.3 |
4 | 73 | F | NHW | EGFR exon 19 deletion | 0 | 4 | Afatinib, Osimertinib | Good | PR | 16 | 19.9 |
5 | 79 | F | NHW | ERBB2 L755 | 0 | 7 | Afatinib | Good | PR | 23.9 | 38.4 |
6 | 43 | M | Asian | EGFR exon 19 deletion | 50% | 4 | Osimertinib | Poor | PD | 0.7 | 7.8 |
7 | 69 | M | NHW | EGFR L858R, EGFR T790M | 30% | 6 | Osimertinib | Poor | PD | 4.5 | 14.5 |
8 | 76 | F | H | EGFR L858R, EGFR T790M, C797S | 5% | 5 | Afatinib, Brigatinib | Poor | PD | 2 | 3.9 |
9 | 57 | F | Asian | EGFR L858R, EGFR T790M | 0 | 8 | Osimertinib | Poor | PR | 20.4 | 21.5 |
10 | 85 | F | Asian | EGFR L858R, EGFR T790M | 0 | 9 | Osimertinib | Poor | PR | 4.4 | 6.5 |
11 | 55 | M | Asian | EGFR exon 19 deletion | 0 | 7.4 | Osimertinib | Good | SD | 21 | 33 |
12 | 68 | F | NHW | EGFR exon 19 deletion | 70% | 7 | Osimertinib | Poor | SD | 0.9 | 7.9 |
13 | 67 | F | NHW | EGFR L858R | 100% | 16 | Osimertinib | Poor | SD | 6 | 6 |
14 | 79 | M | Asian | EGFR L858R | 0 | 2 | Erlotinib | Good | PR | 10.5 | 26.2 |
15 | 79 | M | Asian | EGFR L858R, EGFR T790M | 0 | 2 | Osimertinib | Good | PR | 105 | 26.2 |
16 | 53 | F | Asian | EGFR exon 19 deletion | 50% | 4 | Erlotinib | Good | PR | 25.1 | 49 |
17 | 82 | F | Asian | METTL25-ALK fusion | 15% | 2 | Alectinib | Good | PR | 37 | 37 |
18 | 73 | M | Asian | MET amplification | 30% | 14 | Crizotinib | Good | PR | 10.6 | 10.7 |
19 | 45 | M | Asian | EML4-ALK V3a/b fusion | 50% | 6 | Alectinib | Good | PR | 16 | 38.4 |
20 | 64 | M | NHW | EGFR exon 19 deletion | 1% | 4 | Osimertinib | Good | PR | 12.6 | 21.3 |
21 | 58 | M | Asian | EML4-ALK V4a/b fusion | 50% | 0 | Alectinib | Good | PR | 60.6 | 60.6 |
22 | 60 | F | Asian | KIF5b-RET fusion | 80% | 0 | Alectinib | Poor | PD | 6.2 | 14.1 |
23 | 79 | F | NHW | EGFR exon 20 insertion | 10% | 7.4 | Poziotinib | Good | PD | 8.7 | 18.6 |
24 | 72 | F | NHW | EGFR exon 20 insertion | 0 | 3.7 | Osimertinib | Poor | PD | 3.7 | 3.7 |
25 | 56 | F | Asian | EGFR exon 19 deletion | > 1% | 6.3 | Osimertinib | Poor | PD | 2.1 | 2.1 |
26 | 59 | F | NHW | EGFR L858R | 8% | 2.5 | Osimertinib | Poor | SD | 10 | 15.9 |
27 | 51 | F | Asian | EGFR exon 19 deletion | 6% | 11.6 | Osimertinib | Poor | PD | 3.9 | 3.9 |
28 | 61 | F | NHW | CCDC6-RET fusion | 0 | 2.6 | Selpercatinib | Good | SD | 5.8 | 5.8 |
29 | 59 | M | NHW | HER2 amplification | 0 | 9.5 | Afatinib | Good | SD | 8 | 8 |
30 | 69 | F | NHW | MET exon 14 mutation | 25% | 11 | Campactinib | Good | PR | 1.9 | 1.9 |
31 | 66 | F | NHW | CD47-MET fusion; MET missense mutation | 0 | 1.1 | Campactinib | Good | PR | 1.5 | 1.5 |
32 | 73 | M | NHW | EGFR exon 19 deletion | 0 | 1 | Osimertinib | Good | PR | 6.3 | 9.5 |
33 | 74 | M | NHW | ERBB2 exon 20 insertion | 0 | 3.2 | Poziotinib | Poor | PD | 1.6 | 18.1 |
34 | 79 | F | NHW | EGFR Exon 20 insertion | 10% | 7.4 | Osimertinib | Poor | PD | 4.1 | 18.6 |